{"id":"W4415451907","doi":"10.1016/j.cllc.2025.10.018","title":"Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Epidermal growth factor receptor; Placebo; Biomarker; Epidermal growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009865458,0.0006261774,0.002727794,0.0003266732,0.0002721106,0.00005111996,0.0003118219,0.000461135,0.001311515],"category_scores_gemma":[0.001305706,0.0005058021,0.0009586297,0.0008045331,0.0003088493,0.0001908124,0.0001558914,0.0009464483,0.00001594407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001389549,"about_ca_system_score_gemma":0.003856136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00184245,"about_ca_topic_score_gemma":0.0003130976,"domain_scores_codex":[0.9943456,0.000539801,0.002548381,0.001228614,0.0004015615,0.0009360438],"domain_scores_gemma":[0.9954295,0.002350078,0.0006678603,0.0006312433,0.0004060878,0.0005152166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9020607,0.004710499,0.02794349,0.001123245,0.003778343,0.0001052915,0.001871353,0.0003116752,0.0007132998,0.0003971267,0.02053163,0.03645329],"study_design_scores_gemma":[0.9794508,0.001183461,0.001602479,0.001415448,0.00366026,0.000001505152,0.0001627314,0.004323374,0.002080235,0.0001164521,0.005434125,0.0005691068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9534802,0.01738513,0.001202115,0.00446932,0.006057872,0.0113454,0.0006174467,0.000224311,0.005218141],"genre_scores_gemma":[0.9701954,0.005066997,0.001455912,0.003825182,0.001205612,0.006776501,0.0003323937,0.000105426,0.01103659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07739007,"threshold_uncertainty_score":0.9997393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03420173911946064,"score_gpt":0.4352266216902665,"score_spread":0.4010248825708058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}